These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25213365)

  • 1. Update on the use of biologics in vasculitides.
    Vishwanath S; Relan M; Shen L; Ambrus JL
    Curr Pharm Biotechnol; 2014; 15(6):558-62. PubMed ID: 25213365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and management of small vessel vasculitides].
    Pettersson T; Karjalainen A
    Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the use of biologic agents for the treatment of systemic vasculitis.
    Chung SA; Seo P
    Curr Opin Rheumatol; 2009 Jan; 21(1):3-9. PubMed ID: 19077713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM; D'Cruz DP
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell-targeted therapy in systemic vasculitis.
    Lally L; Spiera R
    Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B cell in vasculitis.
    Walsh M; Jayne D
    Pediatr Nephrol; 2009 Jul; 24(7):1267-75. PubMed ID: 18931860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ANCA-associated vasculitis].
    Holle JU
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of vasculitis.
    Chan M; Luqmani R
    Expert Opin Pharmacother; 2009 Jun; 10(8):1273-89. PubMed ID: 19445559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies for systemic necrotizing vasculitides.
    Guillevin L; Pagnoux C
    Allergol Int; 2007 Jun; 56(2):105-11. PubMed ID: 17460440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of primary systemic vasculitis].
    de Groot K; Gross WL; Hellmich B
    Internist (Berl); 2003 Dec; 44(12):1541-8. PubMed ID: 14689197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides.
    Guillevin L; Pagnoux C
    Isr Med Assoc J; 2008 Jan; 10(1):89-91. PubMed ID: 18300585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis.
    Barra L; Yang G; Pagnoux C;
    Autoimmun Rev; 2018 Jul; 17(7):683-693. PubMed ID: 29729444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents.
    Pipitone N; Olivieri I; Salvarani C;
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S139-61. PubMed ID: 22640657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What place for the new biologics in the treatment of necrotising vasculitides.
    Jayne D
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S1-5. PubMed ID: 16859587
    [No Abstract]   [Full Text] [Related]  

  • 19. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
    Flossmann O; Jones RB; Jayne DR; Luqmani RA
    Ann Rheum Dis; 2006 Jul; 65(7):841-4. PubMed ID: 16769779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides.
    de Groot K; Jayne D
    Clin Nephrol; 2005 Dec; 64(6):480-4. PubMed ID: 16370164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.